Sonoma Biotherapeutics is engineering regulatory T cells (Tregs) to create therapies to treat serious autoimmune and inflammatory diseases. An unbalanced immune system can cause the body to attack its own tissues. Treg cells act as sentinels that survey the body for unwanted immune attacks and rebalance the immune system. Through engineering of Tregs, Sonoma is aiming to treat and possibly cure autoimmune and inflammatory diseases by restoring homeostasis in the immune system. Sonoma is advancing a diverse pipeline with several programs in early-stage clinical trials. This includes SBT-77-7101, a Treg cell therapeutic for the treatment of rheumatoid arthritis.

Sonoma Biotherapeutics

Founded: 2019
Location: South SF, CA
Employee range: 50 - 200
Clinical stage: Clin0
Therapy area: Autoimmune &amp; inflammatory diseases
Drug types: RHU, IMM, GI
Lead product: SBT-11-5301
Funding: $265M B Jul 2021; $30M A Oct 2020; $40M A Feb 2020

Drug notes:

About:

Jobs: